stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Revenue
Travere Therapeutics, Inc.'s revenue for fiscal 2025 was $490.7M, up 110.5% from $233.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $651.0M. Over the past ten years it has ranged from $99.9M (fiscal 2015) to $490.7M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. Travere Therapeutics, Inc. ranks 37th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $490.7M | 110.45% |
| FY2024 | $233.2M | 60.55% |
| FY2023 | $145.2M | 32.69% |
| FY2022 | $109.5M | (16.97%) |
| FY2021 | $131.8M | (33.52%) |
| FY2020 | $198.3M | 13.11% |
| FY2019 | $175.3M | 6.75% |
| FY2018 | $164.2M | 6.01% |
| FY2017 | $154.9M | 15.98% |
| FY2016 | $133.6M | 33.74% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $224.6M | 32.42% |
| Jun 2026 | $169.6M | 33.32% |
| Mar 2026 | $127.2M | (1.92%) |
| Dec 2025 | $129.7M | (21.33%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR compare | $1.3B |
| TVTX Travere Therapeutics, Inc. | $651.0M |
| CRSP CRISPR Therapeutics AG compare | $25.2M |
| COGT Cogent Biosciences, Inc. compare | $23.2M |
| DNTH Dianthus Therapeutics, Inc. compare | $2.7M |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| DFTX Definium Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
| MANE Veradermics Incorporated compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TVTX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement